SCHEMBL5358453

SCHEMBL5358453

CCc1ccc(C=C2C(=O)Nc3ccc(S(=O)(=O)NC)cc32)o1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 6/20 0.53
KDR P35968 4/20 0.52
CDK2 P24941 2/20 0.52
PTPN1 P18031 8/20 0.50
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.50
G6PD P11413 1/20 0.50
KMT2A Q03164 1/20 0.50
NTRK1 P04629 1/20 0.48
FCER2 P06734 1/20 0.48
SYK P43405 1/20 0.48
NTRK3 Q16288 1/20 0.48
NTRK2 Q16620 1/20 0.48
PTPN2 P17706 2/20 0.48
LCK P06239 3/20 0.47
FYN P06241 3/20 0.47
YES1 P07947 3/20 0.47
FGFR1 P11362 3/20 0.47
PDGFRB P09619 2/20 0.47
AURKA O14965 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7139469 0.90 SRC (0.52) SRCKDRCDK2PTPN1MEN1
SCHEMBL5358670 0.85 MEN1 (0.60) SRCKDRCDK2MEN1POLB
SCHEMBL5357946 0.84 RET (0.64) SRCKDRCDK2MEN1POLB
SCHEMBL5361704 0.83 MGAT2 (0.57) PTPN1MEN1KMT2APTPN2
SCHEMBL5368250 0.82 SRC (0.55) SRCKDRCDK2MEN1POLB
SCHEMBL7138289 0.80 SRC (0.58) SRCKDRCDK2NTRK1FCER2
SCHEMBL5373623 0.80 SRC (0.55) SRCKDRCDK2MEN1POLB
SCHEMBL5368474 0.80 EGFR (0.61) SRCKDRCDK2NTRK1FCER2
SCHEMBL5361707 0.79 ALDH1A1 (0.67) SRCKDRCDK2NTRK1FCER2
SCHEMBL7132307 0.78 SRC (0.55) SRCKDRCDK2NTRK1FCER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK SRC 189/4885KDR 239/4885CDK2 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.